Hepatitis Monthly
Official Journal of Research Center for Gastroenterology and Liver Diseases
Crossref
1. Sustained serological and complete responses in HBeAg-positive patients treated with Peginterferon alfa-2b: a 6-year long-term follow-up of a multicenter, randomized, controlled trial in China
- Jian Sun
- Huiguo Ding
- Guofeng Chen
- Guiqiang Wang
- Lai Wei
- Jiming Zhang
- Qing Xie
- Mobin Wan
- Hong Tang
- Shijun Chen
- Zhiliang Gao
- Yuming Wang
- Dazhi Zhang
- Wenxiang Huang
- Jifang Sheng
- Qin Ning
- Dongliang Yang
- Jian Lu
- Chen Pan
- Yuxiu Yang
- Jue Wang
- Chuanzhen Sun
- Qixin Wang
- Jinlin Hou
2. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs
- Jing Huang
- Ka Zhang
- Wenli Chen
- Jinyao Liao
- Xiaodan Luo
- Ren Chen
3. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy
- Meng-Lan Wang
- Juan Liao
- Bing Wei
- Dong-Mei Zhang
- Ming He
- Ming-Chuan Tao
- En-Qiang Chen
- Hong Tang